Providing tobacco cessation treatment to patients with cancer is critically important for improving a broad range of cancer-relevant outcomes, including surgical wound healing, treatment morbidity, efficacy of radiation and chemotherapy, time to cancer recurrence, disease progression, development of second primary cancers, and, ultimately, mortality. 1,2 Although most patients with cancer who smoke want to quit, notably limited availability and markedly low rates of engagement with smoking cessation treatment are pressing concerns. 2,3 Numerous scientific and professional organizations, including ASCO, the National Comprehensive Cancer Network, the American Association for Cancer Research, and the National Cancer Institute (NCI), have recognized these issues as high priority and supported practice guidelines and initiatives to develop new and enhanced infrastructures for addressing tobacco use among patients with cancer who smoke.